Sironax has recently completed its Phase I clinical trial for SIR2501, an innovative drug candidate with potential to treat neurodegenerative and other neurological diseases. This was a randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SIR2501 in healthy volunteers. The trial was conducted primarily in Australia with a bridging cohort in China.
Sironax team is excited with the Phase I results, which align with preclinical expectations and support the advancement of SIR2501 into patient studies. The complete data analysis will be presented at upcoming medical conferences and/or through peer-reviewed clinical publications.
Preclinical studies have demonstrated SIR2501’s neuroprotective effects in models of amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, and other conditions. Building on preclinical findings and the Phase I results, Sironax is planning to advance SIR2501 into patient studies soon for neurological disorders, an area with significant medical unmet need. .
About Sironax
Headquartered in Waltham, Massachusetts, Sironax is a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases. The company has built a diverse pipeline of programs by targeting contributors of aging: degeneration, metabolic dysfunction, and inflammation. Sironax is conducting clinical studies with SARM1 inhibitor SIR2501, NAMPT activator SIR4156, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. For more information, visit sironax.com.